A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

[1]  P. Benfield,et al.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. , 1996, Drugs.

[2]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[3]  B. Brooks,et al.  Clinical epidemiology of amyotrophic lateral sclerosis. , 1996, Neurologic clinics.

[4]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.

[5]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[6]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[7]  F. Norris,et al.  Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.

[8]  J. R. Brinkmann,et al.  The natural history of amyotrophic lateral sclerosis , 1993, Neurology.

[9]  D. B. Williams,et al.  Motor neuron disease (amyotrophic lateral sclerosis). , 1991, Mayo Clinic proceedings.

[10]  V. Meininger,et al.  A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis , 1989, Neurology.

[11]  F. Norris,et al.  The administration of guanidine in amyotrophic lateral sclerosis , 1974, Neurology.